The effective application of phentermine implies introducing changes to lifestyle and eating habits, including an obligatory reduction in the amount of calories consumed on a daily basis.
As the obesity problem has started gaining momentum it became evident the conventional methods demonstrate insufficient effectiveness as for weight loss results, which heralded the era of pharmaceutical means for weight loss management and in 1959 the first phentermine-based preparation, Ionamin was included in the list of approved medications by FDA. A refined formulation of phentermine medication, Adipex, was approved by FDA and released for sales in 1990.
There’s no official statistics as for Adipex sales; however, according to a number of sources over 50 million prescriptions for phentermine-based meds has been issued since the release of Ionamin. Affordability is one of the most crucial advantages of the drug, it outperforms sibutramine meds and considered to be a more cost-effective option due to its short term nature of treatment.
The most recent and comprehensive studies of Adipex were conducted in South Korea – a research conducted in 2006 included a variety of aspects, including the effectiveness and the state of affairs in the market (running ahead, the similarities between the US and Korean markets are obvious).
Thus, in the Asian country the rivals of Adipex are represented by Reductil and Xenical, and these drugs inferior to the phentermine-based medication in terms of pricing (Adipex is roughly 75 – 80% cheaper). In the US and Korea the drug is available by prescription only, the price range starts from $50 per 30 pills package, while generic medications can be accessed 25 – 60% cheaper.
The study among Korean patients, suffering from obesity with no significant conditions and a body mass index higher than 25kg/m2, continued for 12 weeks (with a 2 weeks run-in). The results have confirmed the effectiveness of treatment: along with general weight reduction, the level of bad cholesterol was reduced as well, decreasing the risk of cardio-vascular disease associated with excessive weight.
The treatment course had a positive, shortening effect on waist circumference. 80% of participants have managed to reduce their weight by at least 5% (and more), while a half of these patients has achieved 10% weight loss results. The studies included the educational program LEARN, focusing on how to change eating behaviour and add regular exercising to the lifestyle – the recommendations a patient must follow to achieve optimal weight loss results.
Perhaps, the most essential reason for the continuation of treatment with the 50+ years old drug is the absence of any significant side effects and decent results produced in a wide range of studies and surveys. Adipex feedback page at drugs.com features the reviews starting from the mid 00’s, and the current rating of the drug is 9.1 out of 10 – frankly speaking, a rare phenomenon for a pharmaceutical market.
Scientists still claim the potential of the drug is yet to be fully revealed, especially in combinative treatment, and several attempts were made with the release of fenfluramin – the combination of substances demonstrated the weight loss results going beyond 10% of decrease in mass. Nevertheless, the license for fenfluramin was revoked back in 1997, the reason – strong adverse side reactions (leading to pulmonary hypertension, valvular heart disease, etc.) in 15 patients out of 1,000.